Non-alcoholic Fatty Liver Diseases (NAFLD) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

From the Editor ’s Desk...
Metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). However, given that MASLD requires at least one cardiometabolic risk factor, questions were raised as to whether new evidence would need to be generated for MASLD. In this issue, Younossi and coworkers compared the clinical profile and outcomes of NAFLD to MASLD using a tertiary-care NAFLD database and NHANES-III. Ninety-nine percent of included patients met MASLD criteria while 95% met MASLD criteria on BMI only. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 17, 2024 Category: Gastroenterology Authors: Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli Tags: From the Editor's Desk Source Type: research

Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment
ConclusionThe present GL is directed to all physicians addressing people with obesity —working in hospitals, territorial services or private practice—and to general practitioners and patients. The recommendations should also consider the patient’s preferences and the available resources and expertise. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - April 17, 2024 Category: Endocrinology Source Type: research

Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against non-alcoholic fatty liver disease
CONCLUSIONS: Ursolic acid could improve immune inflammation in NAFLD by modulating SPP1-mediated Th17 cell differentiation via the ERK signaling pathway, which is orchestrated jointly by ITGB1 and CD44, emerging as a linchpin in this molecular cascade.PMID:38623614 | DOI:10.3350/cmh.2024.0047 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - April 16, 2024 Category: Gastroenterology Authors: Yiyuan Zheng Lina Zhao Zhekun Xiong Chaoyuan Huang Qiuhong Yong Dan Fang Yugang Fu Simin Gu Chong Chen Jiacheng Li Yingying Zhu Jing Liu Fengbin Liu Yong Li Source Type: research

Cancers, Vol. 16, Pages 1513: Time-Restricted Feeding Attenuates Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma in Obese Male Mice
In this study, we tested a time-restricted feeding (TRF) nutritional intervention in mouse models of MASH and HCC. We show that TRF abrogated metabolic dysregulation induced by a Western diet without any calorie restriction or weight loss. TRF improved insulin sensitivity and reduced hyperinsulinemia, liver steatosis, inflammation, and fibrosis. Importantly, TRF inhibited liver tumors in two mouse models of obesity-driven HCC. Our data suggest that TRF is likely to be effective in abrogating MASH and HCC and warrant further studies of time-restricted eating in humans with MASH who are at higher risk of developing HCC. (Source: Cancers)
Source: Cancers - April 16, 2024 Category: Cancer & Oncology Authors: Manasi Das Deepak Kumar Consuelo Sauceda Alexis Oberg Lesley G. Ellies Liping Zeng Lily J. Jih Isabel G. Newton Nicholas J. G. Webster Tags: Article Source Type: research

Incretin-based investigational therapies for the treatment of MASLD/MASH
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common form of chronic liver disease. It exists as either simple steatosis or its more progressive form, metabolic dysfunction-associated steatohepatitis (MASH), formerly, non-alcoholic steatohepatitis (NASH). The global prevalence of MASLD is estimated to be 32% among adults and is projected to continue to rise with increasing rates of obesity, type 2 diabetes, and metabolic syndrome. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - April 16, 2024 Category: Endocrinology Authors: Bram Brouwers, Girish Rao, Yuanyuan Tang, Ángel Rodríguez, Leonard C Glass, Mark L Hartman Source Type: research

Alpha lipoic acid administration improved both peripheral sensitivity to insulin and liver clearance of insulin reducing potential risk of diabetes and nonalcoholic fatty liver disease in overweight/obese PCOS patients
Volume 40, Issue 1, December 2024 . (Source: Gynecological Endocrinology)
Source: Gynecological Endocrinology - April 16, 2024 Category: Endocrinology Authors: Alessandro D. GenazzaniChristian BattipagliaLaura RusceGreta PrampoliniClaudia AioFrancesco RicciardielloMartina FoschiAlessandra SponzilliElisa SempriniTabatha PetrilloGynecological Endocrinology Center, Department of Obstetrics and Gynecology, Universit Source Type: research

Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
ConclusionsThe quantitative measurement system for M2BPGi depends on liver fibrosis and inflammation, regardless of etiology. Liver inflammation complicates the interpretation of M2BPGi-Qt results when assessing the fibrosis stage. (Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - April 16, 2024 Category: Gastroenterology Source Type: research

Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms
Planta Med DOI: 10.1055/a-2277-4805Non-alcoholic fatty liver disease (NAFLD), with a global prevalence of 25%, continues to escalate, creating noteworthy concerns towards the global health burden. NAFLD causes triglycerides and free fatty acids to build up in the liver. The excessive fat build-up causes inflammation and damages the healthy hepatocytes, leading to non-alcoholic steatohepatitis (NASH). Dietary habits, obesity, insulin resistance, type 2 diabetes, and dyslipidemia influence NAFLD progression. The disease burden is complicated due to the paucity of therapeutic interventions. Obeticholic acid is the only approv...
Source: Planta Medica - April 15, 2024 Category: Drugs & Pharmacology Authors: Banerjee, Tanmoy Sarkar, Arnab Ali, Sk Zeeshan Bhowmik, Rudranil Karmakar, Sanmoy Halder, Amit Kumar Ghosh, Nilanjan Tags: Reviews Source Type: research

Metabolic Syndrome and Cardiac Vessel Remodeling Associated with Vessel Rarefaction: A Possible Underlying Mechanism May Result from a Poor Angiogenic Response to Altered VEGF Signaling Pathways
J Vasc Res. 2024 Apr 12:1-9. doi: 10.1159/000538361. Online ahead of print.ABSTRACTBACKGROUND: Elevated mortality rates in patients with metabolic syndrome (MetS) are partly due to adverse remodeling of multiple organs, which may lead to cardiovascular disease, nonalcoholic fatty liver disease, kidney failure, or other conditions. MetS symptoms, such as obesity, hypertension, hyperglycemia, dyslipidemia, associated with insulin and leptin resistance, are recognized as major cardiovascular risk factors that adversely affect the heart.SUMMARY: Pathological cardiac remodeling is accompanied by endothelial cell dysfunction whi...
Source: Cell Research - April 14, 2024 Category: Cytology Authors: Krzysztof Bartkowiak Mateusz Bartkowiak Ewa Jankowska-Steifer Anna Ratajska Marek Kujawa Olga Anio łek Justyna Niderla-Bieli ńska Source Type: research

RNF31 alleviates liver steatosis by promoting p53/BNIP3-related mitophagy in hepatocytes
CONCLUSIONS: The findings highlight RNF31's essential role in the regulation of mitochondrial homeostasis in hepatocytes, emphasizing its potential as a therapeutic target for NAFLD.PMID:38615890 | DOI:10.1016/j.freeradbiomed.2024.04.214 (Source: Free Radical Biology and Medicine)
Source: Free Radical Biology and Medicine - April 14, 2024 Category: Biology Authors: Yifei Chen Fuji Yang Yujie Shi Jingyu Sheng Yanjin Wang Liting Zhang Jing Zhou Yi Jin Yongmin Yan Source Type: research

Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population
The diagnosis and comprehension of nonalcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD) are gaining a better understanding. In this s... (Source: Lipids in Health and Disease)
Source: Lipids in Health and Disease - April 14, 2024 Category: Lipidology Authors: Chenbing Liu, Nan Li, Di Sheng, Yahong Shao, Lihong Qiu, Chao Shen and Zhong Liu Tags: Research Source Type: research

Association between endocrine-disrupting chemical mixtures and non-alcoholic fatty liver disease with metabolic syndrome as a mediator among adults: A population-based study in Korea
Ecotoxicol Environ Saf. 2024 Apr 12;276:116310. doi: 10.1016/j.ecoenv.2024.116310. Online ahead of print.ABSTRACTEndocrine-disrupting chemicals (EDCs) may play a role in non-alcoholic fatty liver disease (NAFLD); however, studies on the combined effects of EDC mixtures on NAFLD development are limited. Here, we explored the association between exposure to EDC mixtures and NAFLD and investigated the potential mediating role of metabolic syndrome (MetS). We included participants from the Korean National Environmental Health Survey Cycle 4 (2018-2020) and quantified the urinary concentrations of various EDCs-eight phthalate m...
Source: Ecotoxicology and Environmental Safety - April 13, 2024 Category: Environmental Health Authors: Bohyun Park Byungmi Kim Chung Ho Kim Hyun Jin Oh Bomi Park Source Type: research

Potential diagnostic markers shared between non-alcoholic fatty liver disease and atherosclerosis determined by machine learning and bioinformatic analysis
CONCLUSION: We identified RPS6KA1 and SERPINA3 as potential diagnostic markers for NAFLD and AS. The most promising marker for a diagnosis of NAFLD and AS might be RPS6KA1, whereas SERPINA3 is the most closely related gene for NASH and AS. We believe that further exploration of these core genes will reveal the etiology and a pathological relationship between NAFLD and AS.PMID:38606153 | PMC:PMC11007109 | DOI:10.3389/fmed.2024.1322102 (Source: Atherosclerosis)
Source: Atherosclerosis - April 12, 2024 Category: Cardiology Authors: Lihong Wang Wenhui He Xilin Wang Jianrong Wang Xiaojuan Wei Dongzhi Wu Yundan Wu Source Type: research

Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
CONCLUSION: The liver size of persons with fatty liver was substantially more considerable than healthy people. The size of the liver was substantially linked with sex, age, BMI, fatty liver, and hepatic steatosis grade. A straightforward way to predict fatty liver is to use ultrasonography to determine the size of the liver.PMID:38605772 | PMC:PMC11006049 | DOI:10.4103/jfmpc.jfmpc_94_23 (Source: Primary Care)
Source: Primary Care - April 12, 2024 Category: Primary Care Authors: Maryam Dorostghol Mohammad M Gharibvand Mohammad G Hanafi Azim Motamedfar Source Type: research